Hepburn P J, Oliver R T, Riley P A, Hill B T, Masters J R
Urol Res. 1985;13(1):27-34. doi: 10.1007/BF00571753.
Many chemotherapeutic drugs have been used to treat patients with advanced bladder cancer, but few of these have been evaluated adequately in phase II clinical trials. Continuous cell lines provide one means for comparing the in vitro cytotoxicities of anticancer agents. In this study, a continuous cell line derived from a transitional cell cancer of the human bladder, which still produces tumours histologically similar to the tumour of origin on xenotransplantation, was used to measure the in vitro cytotoxicities of twelve chemotherapeutic drugs by clonogenic assay. The most cytotoxic agents tested were methotrexate, mitoxantrone, adriamycin, mitomycin C and cisplatin. These in vitro findings are compatible with the activity of these drugs given systemically as single agents in phase II clinical trials in patients with advanced bladder cancer.
许多化疗药物已被用于治疗晚期膀胱癌患者,但其中很少有药物在II期临床试验中得到充分评估。连续细胞系为比较抗癌药物的体外细胞毒性提供了一种方法。在本研究中,使用一种源自人膀胱移行细胞癌的连续细胞系,该细胞系在异种移植时仍能产生组织学上与原发肿瘤相似的肿瘤,通过克隆形成试验来测定12种化疗药物的体外细胞毒性。测试的细胞毒性最强的药物是甲氨蝶呤、米托蒽醌、阿霉素、丝裂霉素C和顺铂。这些体外研究结果与这些药物在晚期膀胱癌患者的II期临床试验中作为单药全身给药的活性相符。